L. Becker Hewes is Chief Medical Officer at Blueprint Medicines Corp (BPMC). They have made 11 open-market trades across 1 company since 2021, most recently 2026-01-05.
CIK 0001840110
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $88.23 | $1.8M | +5.7% | -6.3% | +49.4% |
| BPMC | SELL · 10b5-1 | 2024-06-04 | 2024-06-06 | $104.91 | $509K | +2.8% | +12.1% | -10.8% |
| BPMC | SELL · 10b5-1 | 2024-05-31 | 2024-06-04 | $105.98 | $8.3M | +3.4% | +9.5% | -9.3% |
| BPMC | SELL | 2024-03-07 | 2024-03-11 | $90.69 | $562K | +1.0% | +1.5% | +16.7% |
| BPMC | SELL | 2023-06-05 | 2023-06-07 | $52.05 | $146K | +7.6% | +0.5% | -16.5% |
| BPMC | SELL | 2023-03-06 | 2023-03-08 | $45.70 | $136K | +3.2% | -3.4% | +32.1% |
| BPMC | SELL | 2022-06-06 | 2022-06-08 | $59.90 | $335K | -19.8% | -10.4% | +11.9% |
| BPMC | SELL | 2022-03-16 | 2022-03-18 | $60.00 | $133K | +0.6% | +0.4% | -27.7% |
| BPMC | SELL | 2022-03-07 | 2022-03-08 | $56.19 | $118K | +17.5% | +23.4% | +4.6% |
| BPMC | SELL | 2021-12-15 | 2021-12-17 | $100.00 | $73K | +8.1% | -27.8% | -38.0% |
| BPMC | SELL | 2021-11-15 | 2021-11-17 | $115.49 | $168K | -13.8% | -8.0% | -25.5% |
| BPMC | SELL | 2021-10-15 | 2021-10-19 | $102.66 | $150K | +10.1% | +8.0% | -28.4% |
| BPMC | SELL | 2021-09-15 | 2021-09-17 | $101.19 | $2.4M | -0.4% | -4.8% | -4.3% |
| BPMC | SELL | 2021-06-02 | 2021-09-17 | $89.03 | $230K | -0.4% | -4.8% | -4.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.